SYNAGEVA BIOPHARMA CORP (GEVA) has 22 open-market insider trades by 7 insiders since 2012. The most active filer is Daniel R. Tisch, 10%.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Felix Baker | Dir10% | — | 5 | $270.7M | 2015-06-22 |
| BAKER Bros. Advisors L.P. via Julian Baker | Dir10% | — | 2 | $133.8M | 2015-01-07 |
| 14159, L.P. | Dir10% | — | 2 | $100.3M | 2013-09-25 |
| Julian Baker | Dir10% | — | 1 | $36.5M | 2015-06-22 |
| Thomas J. Tisch | Dir | — | 4 | $35.7M | 2015-06-22 |
| Srinivas Akkaraju | — | — | 2 | $24.7M | 2012-06-27 |
| Daniel R. Tisch | 10% | — | 6 | $7.8M | 2012-07-12 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Glen Williams | SVP & Technical Operations | Sell | $2.8M | 2015-06-08 |
| Glen Williams | SVP & Technical Operations | Sell | $343K | 2015-05-06 |
| Anthony Quinn | EVP & CMO & Head of R&D | Sell | $1.1M | 2015-04-27 |
| Anthony Quinn | EVP & CMO & Head of R&D | Sell | $1.1M | 2015-04-21 |
| Anthony Quinn | EVP & CMO & Head of R&D | Sell | $1.1M | 2015-04-15 |
| Glen Williams | SVP & Technical Operations | Sell |
Companies that share insiders with GEVA, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| $4.1M |
| 2015-04-07 |
| Anthony Quinn | EVP & CMO & Head of R&D | Sell | $2.8M | 2015-04-06 |
| Chris Heberlig | SVP & Finance and Business Ops. | Sell | $774K | 2015-03-11 |
| Carsten Boess | CFO & SVP | Sell | $4.2M | 2015-02-17 |
| BAKER Bros. Advisors L.P. | Director & 10% | Buy | $94.2M | 2015-01-07 |
| Chris Heberlig | President & Finance | Sell | $556K | 2014-12-29 |
| Sanj K. Patel | President | Sell | $4.4M | 2014-12-17 |
| Carsten Boess | CFO & SVP | Sell | $2.0M | 2014-10-28 |
| Mark Alan Goldberg | EVP & Medical & Reg. Strategy | Sell | $52K | 2014-09-19 |
| Mark Alan Goldberg | EVP & Medical & Reg. Strategy | Sell | $883K | 2014-09-16 |